27-Hydroxycholesterol: The first identified endogenous SERM

Trends in Endocrinology and Metabolism

Volumn 22, Issue 4, 2011, Pages 130-135

  Umetani, Michihisa ^a   Shaul, Philip W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; CHOLESTANETRIOL 26 MONOOXYGENASE; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYSTEROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

BONE MINERALIZATION; BREAST CANCER; CANCER CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CATABOLISM; CELL GROWTH; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; GENE EXPRESSION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CALCIFICATION, PHYSIOLOGIC; CARDIOVASCULAR SYSTEM; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; MICE; MODELS, BIOLOGICAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79953160837     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2011.01.003     Document Type: Review

References (48)

1. McDonnell D.P. Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen. J. Soc. Gynecol. Investig. 2000, 7:S10-S15.
2. McDonnell D.P. The molecular determinants of estrogen receptor pharmacology. Maturitas 2004, 48(Suppl. 1):S7-12.
3. Umetani M., et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 2007, 13:1185-1192.
4. Russell D.W. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid. Res. 2009, 50(Suppl.):S120-S125.
5. Olkkonen V.M., Hynynen R. Interactions of oxysterols with membranes and proteins. Mol. Aspects Med. 2009, 30:123-133.
6. Janowski B.A., et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
7. Björkhem I. Are side-chain oxidized oxysterols regulators also in vivo?. J. Lipid Res. 2009, 50(Suppl):S213-S218.
8. Li-Hawkins J., et al. Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J. Biol. Chem. 2000, 275:16536-16542.
9. Russell D.W. Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 2000, 1529:126-135.
10. Brown A.J., Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 1999, 142:1-28.
11. Björkhem I., Hansson M. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 2010, 396:46-49.
12. Schule R., et al. Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J. Lipid Res. 2010, 51:819-823.
13. Hirayama T., et al. Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol. Res. 2009, 39:149-156.
14. Lee C.Y., et al. Measurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radic. Biol. Med. 2008, 44:1314-1322.
15. Wu Z., et al. Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs and gene CYP7B1. J. Lipid Res. 1999, 40:2195-2203.
16. Stiles A.R., et al. CYP7B1: one cytochrome P450, two human genetic diseases, and multiple physiological functions. J. Biol. Chem. 2009, 284:28485-28489.
17. Omoto Y., et al. Early onset of puberty and early ovarian failure in CYP7B1 knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2814-2819.
18. DuSell C.D., et al. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 2008, 22:65-77.
19. Burkard I., et al. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis 2007, 194:71-78.
20. Duane W.C., Javitt N.B. 27-Hydroxycholesterol: production rates in normal human subjects. J. Lipid Res. 1999, 40:1194-1199.
21. Crisby M., et al. Localization of sterol 27-hydroxylase immuno-reactivity in human atherosclerotic plaques. Biochim. Biophys. Acta 1997, 1344:278-285.
22. Upston J.M., et al. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am. J. Pathol. 2002, 160:701-710.
23. Yamamoto Y., et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J. Biol. Chem. 2006, 281:16625-16631.
24. Deroo B.J., Korach K.S. Estrogen receptors and human disease. J. Clin. Invest. 2006, 116:561-570.
25. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 1999, 340:1801-1811.
26. Brouchet L., et al. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 2001, 103:423-428.
27. Pare G., et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ. Res. 2002, 90:1087-1092.
28. Chambliss K.L., et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J. Clin. Invest. 2010, 120:2319-2330.
29. Zhu Y., et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002, 295:505-508.
30. Hodgin J.B., Maeda N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 2002, 143:4495-4501.
31. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308:1583-1587.
32. Colditz G.A., et al. Menopause and the risk of coronary heart disease in women. N. Engl. J. Med. 1987, 316:1105-1110.
33. Karas R.H. Current controversies regarding the cardiovascular effects of hormone therapy. Clin. Obstet. Gynecol. 2004, 47:489-499.
34. Turgeon J.L., et al. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2000, 304:1269-1273.
35. Hulley S., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613.
36. Rossouw J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
37. Santen R., et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 2010, 95(Suppl. 1):s1-s66.
38. Grodstein F., et al. Understanding the divergent data on postmenopausal hormone therapy. N. Engl. J Med. 2003, 348:645-650.
39. Strong J.P., et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999, 281:727-735.
40. Tejada C., et al. Distribution of coronary and aortic atherosclerosis by geographic location, race, and sex. Lab. Invest. 1968, 18:509-526.
41. Clarkson T.B., Appt S.E. Controversies about HRT - lessons from monkey models. Maturitas 2005, 51:64-74.
42. McPherson K., et al. ABC of breast diseases. Breast cancer - epidemiology, risk factors, and genetics. BMJ 2000, 321:624-628.
43. Patel R.R., et al. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 2007, 14:113-122.
44. Chen S., et al. What do we know about the mechanisms of aromatase inhibitor resistance?. J. Steroid. Biochem. Mol. Biol. 2006, 102:232-240.
45. Manolagas S.C., et al. Sex steroids and bone. Recent Prog. Horm. Res. 2002, 57:385-409.
46. Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur. J. Epidemiol. 2004, 19:1105-1112.
47. Tanko L.B., et al. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women?. Bone 2003, 32:8-14.
48. DuSell C.D., et al. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology 2010, 151:3675-3685.